• Home Dutch
  •  EN 
  • Employee login

Role of cyclooxygenase signalling on vascular dysfunction in the metabolic syndrome.

Print 

Title:   Role of cyclooxygenase signalling on vascular dysfunction in the metabolic syndrome.
Investigator:  SW Landheer
Promotor: RH Henning
Co-promoter(es):  LE Deelman, JH Buikema
 Summary: It was observed that baseline involvement of COX-derived prostaglandins (PG’s) in endothelial (dys-)function (E(D)F) in intrarenal arteries predicted for the degree of renal damage development after 5/6 Nx such that higher contractile PG’s (in normal healthy individuals!) at baseline was correlated with increased future proteinuria. Unpublished studies showed that aortic EDF development in Zucker diabetic fatty rats with DM-2 importantly involved increased contractile PG’s (preliminary data SW Landheer). Recent literature regarding E(D)F in this field additionally highlights the (shift in the) role of PG’s in ageing and pathophysiological conditions, and the role of COX1 vs COX2 herein. Previous work of our group concomitantly highlighted the involvement of caveolae both in EF and myogenic constriction in vascular function, and alterations herein in chronic heart failure. The question addressed in the present project is whether altered vascular COX-signalling in MBS and DM-2 involves shifted COX-1 and/or -2 due to altered caveolar function in MBS and DM-2.
Financing: Junior Scientific Masterclass, MD/PhD bursary
Start: 1-10-2010
End: 1-10-2014

    

Projects
Organ damage and the role of CBS in hibernation.
Mechanisms and modulation of the immune response in sterile sepsis.
The CBS/H2S pathway in the brain.
Platelet dynamics in natural and pharmacologically induced hibernation.
Liver fibrosis and hibernation.
Towards prevention of neuroinflammation in major surgery.
Limiting the impact of stroke.
Identification of kinomic key proteins involved in tachycardia and stretch induced cardiomyocyte remodeling.
Role of epigenetic regulation by histone acetylation in the induction of Atrial Fibrillation.
Reversal of cardiomyocyte remodeling in Atrial Fibrillation; the role of protein degradation and translation modulators.
REVersal of cardiomyocyte structural remodeling and Improvement of functional recoVEry in Atrial Fibrillation: REVIVE.
HSF1 Activators Lower cardiomyocyte damage: towards a novel Therapeutic approach to REVERSE Atrial Fibrillation. HALT&REVERSE
Mutations in HSPB5, HSPB7 and BAG3 lead to juvenile DCM.
New therapeutic targets in diabetic kidney disease. A role of GDF-15?
Role of cyclooxygenase signalling on vascular dysfunction in the metabolic syndrome.
Vascular (Dys-)Function as a Determinant of Susceptibility to Diabetic Nephropathy: a Focus on Myogenic Constriction.